Market Leadership and Brand Recognition: Exact Sciences Corp has established itself as a market leader in the cancer screening industry, particularly with its flagship product, Cologuard.

Return on Equity (ROE): Exact Sciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.5%, the company may encounter ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences Cologuard business also received a boost from updated guidelines released by the United States Preventive Services Task Force. The draft recommended colorectal cancer screening ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At this time, I would like to welcome everyone to the Exact Sciences third-quarter 2024 earnings conference call. [Operator ...

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...

Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point Exact Sciences Q3 EPS loss of $0.21 fell short of analyst ...

Market Leadership and Brand Recognition: Exact Sciences Corp has established itself as a market leader in the cancer screening industry, particularly with its flagship product, Cologuard. The ...

At this time, I would like to welcome everyone to the Exact Sciences third-quarter 2024 earnings ... increasing Cologuard customer satisfaction and brand awareness to all-time highs; receiving ...